Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Bleeding (major and minor) · participants at risk of venous thromboembolism
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (moderate certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Vitamin K antagonists showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (low certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
DOAC showed no clear difference in bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with heparin (high certainty).
1 finding from 1 review
Minor bleeding · people requiring prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Heparin leads to higher bleeding ‐ minor Treatment duration 28 ‐ 42 days compared with placebo (high certainty).
1 finding from 1 review
Minor bleeding · patients with venous thromboembolism.
It is very uncertain whether 10 mg warfarin nomogram changes minor bleeding it is not major bleeding compared with 5 mg warfarin nomogram (very low certainty).
1 finding from 1 review
Deep vein thrombosis · patients with prevention of deep vein thrombosis1
It is very uncertain whether knee length changes deep vein thrombosis (Fixed‐effect analysis) Venous duplex scan,… compared with thigh length graduated compression stockings (very low certainty).
3 findings from 1 review
OR 1.55 [0.78, 3.07]
3 studies · 496 participants
Very low
OR 1.32 [0.43, 4.06]
3 studies · 496 participants
Very low
no estimate extracted
3 studies · 496 participants
Very low
Cardiovascular mortality · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
Amputation · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
Quality of life · people with critical limb ischaemia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events (participants) · people with critical limb ischaemia
PGE1 showed no clear difference in adverse events (participants) compared with inositol niacinate (low certainty).
1 finding from 1 review
Rest‐pain relief · people with critical limb ischaemia
PGE1 showed no clear difference in rest‐pain relief compared with inositol niacinate (low certainty).
1 finding from 1 review
Ulcer healing · people with critical limb ischaemia
PGE1 showed no clear difference in ulcer healing compared with inositol niacinate (low certainty).
1 finding from 1 review